The citrus flavonoid naringenin impairs the in vitro infection of human cells by Zika virus

Allan Henrique Depieri Cataneo(Fundação Carlos Chagas), Diogo Kuczera(Fundação Carlos Chagas), Andrea Cristine Koishi(Fundação Carlos Chagas), Camila Zanluca(Fundação Carlos Chagas), Guilherme Ferreira Silveira(Fundação Carlos Chagas), Thaís Bonato de Arruda(Fundação Carlos Chagas), Andréia Akemi Suzukawa(Fundação Carlos Chagas), Leandro Oliveira Bortot(Universidade de São Paulo), Marcelo Dias‐Baruffi(Universidade de São Paulo), Waldiceu A. Verri(Universidade Estadual de Londrina), Anny Waloski Robert(Fundação Carlos Chagas), Marco Augusto Stimamiglio(Fundação Carlos Chagas), Claudia Nunes Duarte dos Santos(Fundação Carlos Chagas), Pryscilla Fanini Wowk(Fundação Carlos Chagas), Juliano Bordignon(Fundação Carlos Chagas)
Scientific Reports
November 8, 2019
Cited by 101Open Access
Full Text

Abstract

The Zika virus (ZIKV) is an arthropod-borne virus that belongs to the Flaviviridae family. The ZIKV infection is usually asymptomatic or is associated with mild clinical manifestations; however, increased numbers of cases of microcephaly and birth defects have been recently reported. To date, neither a vaccine nor an antiviral treatment has become available to control ZIKV replication. Among the natural compounds recognized for their medical properties, flavonoids, which can be found in fruits and vegetables, have been found to possess biological activity against a variety of viruses. Here, we demonstrate that the citrus flavanone naringenin (NAR) prevented ZIKV infection in human A549 cells in a concentration-dependent and ZIKV-lineage independent manner. NAR antiviral activity was also observed when primary human monocyte-derived dendritic cells were infected by ZIKV. NAR displayed its antiviral activity when the cells were treated after infection, suggesting that NAR acts on the viral replication or assembly of viral particles. Moreover, a molecular docking analysis suggests a potential interaction between NAR and the protease domain of the NS2B-NS3 protein of ZIKV which could explain the anti-ZIKV activity of NAR. Finally, the results support the potential of NAR as a suitable candidate molecule for developing anti-ZIKV treatments.


Related Papers

No related papers found

Powered by citation graph analysis